TUDCA or NAC? That's one of the most common liver-support questions tied to oral AAS, and most users answer it by picking at random or stacking both without knowing what each one does. The real answer depends entirely on which liver markers are elevated. These two supplements are complementary, not interchangeable. One targets bile duct stress, the other targets oxidative damage. To choose correctly, you need to know whether your labs show a cholestatic pattern or a hepatocellular injury pattern.
TUDCA: The Bile Acid Protector
Tauroursodeoxycholic Acid, TUDCA for short, is a hydrophilic bile acid that shields liver cells from the toxic effects of hydrophobic bile acids. It gets the job done through three mechanisms: reducing endoplasmic reticulum (ER) stress, stabilizing mitochondrial membranes, and protecting cholangiocytes, the cells that line the bile ducts. When your blood work comes back with a cholestatic pattern, elevated GGT, elevated bilirubin (particularly direct or conjugated bilirubin), and possibly elevated ALP (alkaline phosphatase), TUDCA is the preferred option.
TUDCA also alters the bile acid pool composition. When you take it, the proportion of hydrophilic bile acids increases, which directly reduces the detergent effect on hepatocyte membranes. In practice, this means GGT and bilirubin trends respond within 2 to 3 weeks of consistent dosing. A common mistake is expecting immediate normalization. If you start TUDCA at 500 mg/day and your GGT is 80 U/L, you should see it drop to the 50s within 10 days, then plateau. If it does not move at all after 3 weeks, the dose is likely too low or the cholestasis is severe enough that you need to reduce the oral AAS dose. Some users also report that splitting the dose across the day works better than a single bolus, because bile acid synthesis is continuous.
Cholestasis means bile flow is impaired and bile acids are accumulating in the liver. Oral AAS, particularly 17-alpha-alkylated compounds, are known to induce this condition by impairing bile acid transport at the canalicular membrane of hepatocytes. TUDCA directly counteracts that mechanism, displacing toxic hydrophobic bile acids and reducing the ER stress response.
The typical dose is 500-1,000 mg per day, taken with food. TUDCA absorbs well orally and reaches therapeutic liver concentrations within hours. Most clinical studies use 500-1,500 mg/day for cholestatic liver disease. For AAS users, 500 mg is a reasonable starting dose, and you can increase to 1,000 mg if GGT remains elevated after 2-3 weeks. Side effects are minimal, just occasional gastrointestinal discomfort at higher doses.
Timing matters more than most realize. TUDCA competes with food for absorption, so taking it with a meal that contains some fat improves its incorporation into bile. Taking it on an empty stomach can cause mild GI discomfort and reduces the peak concentration. If you are running TUDCA alongside oral AAS, take it with your largest meal of the day, usually dinner. For those using injectable AAS with mild GGT elevation, 500 mg once daily is sufficient. For oral cycles with known cholestatic compounds like methyltestosterone or fluoxymesterone, 1,000 mg split into two 500 mg doses is more effective. Do not exceed 1,500 mg unless you have a clinical reason, because higher doses have not shown additional benefit in AAS users and can cause loose stools.
NAC: The Glutathione Recycler
N-Acetylcysteine, or NAC, is a precursor to glutathione, the body's master antioxidant. By replenishing glutathione levels, NAC boosts the liver's ability to neutralize reactive oxygen species and detoxify harmful compounds. Clinically, NAC serves as an antidote for acetaminophen overdose, where it prevents potentially fatal liver necrosis by restoring glutathione reserves faster than the toxin can deplete them.
When your blood work shows a hepatocellular injury pattern, NAC is the preferred option. That means elevated ALT and AST with normal GGT and normal bilirubin. This pattern indicates liver cells are under oxidative stress, but bile flow is intact. It's the most common liver enzyme pattern seen in AAS users, especially those using oral compounds. In this scenario, the ALT and AST elevation reflects increased hepatic workload and oxidative stress rather than cholestatic injury.
NAC's effect on ALT and AST is not immediate. Glutathione depletion takes a few days to reverse, and liver enzyme turnover is slower. You will typically see ALT and AST start to decline after 7 to 10 days of consistent NAC use. A practical scenario: you are on week 3 of Anadrol at 50 mg/day, your ALT is 90 U/L and AST is 70 U/L, GGT is normal. Starting NAC at 1,200 mg/day should bring ALT down to the 60s within two weeks. If it does not, check your hydration and alcohol intake, both of which blunt NAC's effect. NAC also supports kidney function, which matters because oral AAS can strain both organs. Some users prefer the effervescent form for better absorption, but standard capsules work fine if taken with water.
The typical dose is 600 to 1,200 mg per day. NAC has relatively low oral bioavailability, approximately 10%, but that's sufficient for a therapeutic effect. Higher doses, up to 2,000 mg per day, are used in clinical settings, though they may cause gastrointestinal side effects including nausea and loose stools. For optimal absorption, take NAC on an empty stomach.
Mechanism Comparison: TUDCA vs. NAC
The fundamental difference is that TUDCA is cytoprotective. It stabilizes cell membranes and reduces ER stress. NAC, on the other hand, is antioxidant. It scavenges reactive oxygen species and supports the liver's natural detoxification systems. One is a structural protectant, the other is a chemical defense booster. They don't compete; they complement each other.
A common mistake is taking TUDCA for a purely oxidative pattern. If your ALT and AST are high but GGT is normal, TUDCA will not lower those enzymes. It does not have antioxidant activity. Similarly, taking NAC when your GGT is elevated at 60 U/L does nothing for the bile duct stress. You will waste weeks and money, and your blood work will stay elevated, which leads some guys to double the dose or add more supplements. That is a classic error. The other mistake is stopping the supplement as soon as enzymes normalize. The underlying stress from oral AAS persists for the entire cycle. If you stop NAC at week 4 because ALT returned to normal, it will spike again by week 6. Run the supplement for the full cycle, then for 2 weeks after you stop the oral.
TUDCA vs NAC: Head to Head
| Marker | TUDCA | NAC |
|---|---|---|
| Primary Mechanism | Bile acid, ER stress reducer, membrane stabilizer | Glutathione precursor, antioxidant, ROS scavenger |
| Best For | Cholestasis (elevated GGT, bilirubin) | Hepatocellular injury (elevated ALT/AST) |
| Typical Dose | 500-1,000 mg/day with food | 600-1,200 mg/day on empty stomach |
| Evidence Grade | Strong for cholestatic DILI | Strong for oxidative hepatotoxicity |
| Onset of Effect | 24-72 hours | 3-7 days (glutathione replenishment) |
| Side Effects | Minimal; rare GI upset | Nausea, GI upset at high doses |
When to Use Which — The Decision Protocol
Your blood work is the deciding factor when it comes to picking the right supplement. Focus on three markers: GGT, ALT, and AST. Bilirubin gives you extra context on top of those.
When GGT is elevated above 40 U/L or bilirubin is elevated, the pattern is cholestatic. That's when you reach for TUDCA at 500-1,000 mg/day. Elevated GGT means bile duct stress, and TUDCA is the only supplement that directly targets this mechanism. NAC alone won't resolve a cholestatic GGT elevation.
When you see GGT elevated, also check your bilirubin fraction. If direct bilirubin is high, that confirms cholestasis and TUDCA is the right call. If indirect bilirubin is high, that points to hemolysis or Gilbert's syndrome, and TUDCA will not help much. Many AAS users have Gilbert's and get falsely worried about liver damage. A quick way to differentiate: if bilirubin is mildly elevated (under 2 mg/dL) and GGT is normal, it is likely Gilbert's. If GGT is above 40 and bilirubin is creeping up, that is real cholestasis. For those running TUDCA, expect GGT to drop by 30 to 50% within 3 weeks. If it does not, adding a bile acid sequestrant like psyllium husk to reduce enterohepatic recirculation is worth raising with a licensed medical professional first.
When ALT and AST are elevated but GGT and bilirubin stay normal, you're dealing with hepatocellular injury from oxidative stress. That's the most common pattern from oral AAS, and NAC at 600-1,200 mg/day is well-supported for this indication.
If both GGT and ALT/AST are elevated, that mixed pattern points to both cholestatic and oxidative stress, so combine TUDCA and NAC. There are no known drug interactions between the two, and their mechanisms are complementary. A typical combined protocol: TUDCA 500-1,000 mg with breakfast, and NAC 600-1,200 mg on an empty stomach between meals.
When you combine TUDCA and NAC, you are covering both mechanisms, but you also need to monitor for side effects. NAC can cause nausea and loose stools, especially at 1,200 mg or more. TUDCA can cause mild bloating. If you experience both, take them at different times of day, NAC in the morning and TUDCA with dinner. If your enzymes are still climbing after 4 weeks on the combined protocol, do not assume the supplements are failing. Recheck your dose of the oral AAS. Are you taking it with food? Are you drinking enough water? Are you using other hepatotoxic drugs like ibuprofen or alcohol? The supplements will not overcome poor habits. Also, consider adding a liver-friendly diet with reduced fructose and processed fats, which directly lowers oxidative burden.
Quick Decision Protocol
Other Liver Support Options
Milk thistle (silymarin) is the most commonly used liver supplement among AAS users, but the evidence is weaker than for TUDCA or NAC. A Cochrane review found that silymarin's benefit on liver-related mortality largely disappeared once the analysis was restricted to higher-quality trials, and the studies that showed positive effects used pharmaceutical-grade silymarin at doses (420-840 mg/day) far higher than most over-the-counter supplements provide. Milk thistle can be used as a tertiary support, but it should not be the foundation of your liver protection strategy.
SAM-e (S-adenosylmethionine) is sometimes recommended for liver support, but the evidence in AAS users specifically is mixed. SAM-e is better supported for cholestasis in pregnancy and certain chronic liver conditions than for AAS-induced hepatic stress. If cost is not a concern, it can be added as a tertiary option, but TUDCA and NAC should be the foundation.